

Shares of Rockwell Medical, Inc. (NASDAQ:RMTI) rose by 0.25% in the past week and 34.86% for the last 4 weeks. In the past week, the shares has outperformed the S&P 500 by 1.44% and the outperformance increases to 35.9% for the last 4 weeks.

The company shares have rallied 36.33% from its 1 Year high price. On Jun 25, 2015, the shares registered one year high at \$18.04 and the one year low was seen on Dec 15, 2014. The 50-Day Moving Average price is \$12.87 and the 200 Day Moving Average price is recorded at \$10.97. The company executives own 5.5% of Rockwell Medical, Inc. Company shares. In the past six months, there is a change of 0% in the total insider ownership. Institutional Investors own 27.3% of Company shares. During last 3 month period, 7.6% of total institutional ownership has changed in the company shares. Shares of Rockwell Medical, Inc. (NASDAQ:RMTI) ended Thursday session in red amid volatile trading. The shares closed down 0.02 points or 0.12% at \$16.21 with 446,112 shares getting traded. Post opening the session at \$16.25, the shares hit an intraday low of \$16.03 and an intraday high of \$16.49 and the price vacillated in this range throughout the day. The company has a market cap of \$813 million and the number of outstanding shares has been calculated to be 50,169,000 shares. The 52-week high of Rockwell Medical, Inc. (NASDAQ:RMTI) is \$18.04 and the 52-week low is \$8.095. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol. NO COMMENTS LEAVE A
REPLY [Cancel reply](#)

...